Cargando…
Rivastigmine in the treatment of patients with Alzheimer’s disease
Impairment of attention and memory in patients with Alzheimer’s disease (AD) is associated with significantly lower levels of acetylcholine. Inhibition of the breakdown of acetylcholine by blocking the enzymes acetylcholinesterase and butyrylcholinesterase with rivastigmine improves this cholinergic...
Autor principal: | Müller, Thomas |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654625/ https://www.ncbi.nlm.nih.gov/pubmed/19300554 |
Ejemplares similares
-
Rivastigmine for the treatment of dementia associated with Parkinson’s disease
por: Reingold, Jennifer L, et al.
Publicado: (2007) -
Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease
por: Puangthong, Umamon, et al.
Publicado: (2009) -
Update on the use of memantine in Alzheimer’s disease
por: van Marum, Robert J
Publicado: (2009) -
Beta-amyloidolysis and glutathione in Alzheimer’s disease
por: Lasierra-Cirujeda, J, et al.
Publicado: (2013) -
Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease
por: Tampi, Rajesh R, et al.
Publicado: (2007)